Please assess the completion status of the following clinical trial:

Trial Title: A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age 2 to \< 18 years during stage 1 and 1 to \< 18 years during stage 2~* Ewing's sarcoma, soft tissue sarcoma, lymphoma, neuroblastoma, brain tumors or other malignancy (excluding any form of leukemia) requiring treatment with high dose chemotherapy and autologous transplant as rescue therapy~* Eligible for autologous transplantation~* Recovered from all acute significant toxic effects of prior chemotherapy~* Adequate performance status (for patients ≥16 years of age, defined as Karnofsky score \>60 and for patients \<16 years of age, defined as Lansky score \>60)~* Absolute neutrophil count \>0.75 × 10\^9/L~* Platelet count \>50 × 10\^9/L~* Calculated creatinine clearance (using the Schwartz method): during study Stage 1, \>80 mL/min/1.73m\^2 and during study Stage 2, \>60 mL/min/1.73m\^2~* Aspartate aminotransferase(AST)/serum glutamic oxaloacetic transaminase(SGOT), alanine aminotransferase(ALT)/serum glutamic pyruvic transaminase (SGPT) and total bilirubin \<3 × upper limit of normal~* The patient and/or their parent/legal guardian is willing and able to provide signed informed consent~* Patients who are sexually active must be willing to abstain from sexual intercourse or agree to use an approved form of contraception while receiving plerixafor and/or standard mobilization treatment and for at least 3 months following any plerixafor treatment~Exclusion Criteria:~* Any form of leukemia~* A co-morbid condition which, in the view of the Investigator, renders the patient at high-risk from treatment complications~* Previous stem cell transplantation~* Persistent high percentage marrow involvement prior to mobilization will be prohibited.~* On-going toxicities (excluding alopecia) Grade ≥2 resulting from prior chemotherapy~* Acute infection~* Fever (temperature \>38.5°C) - if fever is between 37°C and 38.5°C, infection must be excluded as a cause~* Known HIV seropositivity, AIDS, hepatitis C or active hepatitis B infections~* Positive pregnancy test in post pubertal girls~* History of clinically significant cardiac abnormality or arrhythmia~* Use of an investigational drug which is not approved in any indication either in adults or pediatrics within 2 weeks prior to the first dose of G-CSF to be administered as part of the patient's planned standard mobilization regimen, and/or during the study up until engraftment of the transplant. If patients are on investigational drugs as part of their anti-cancer regimen, this should be discussed with the Sponsor before screening. Drugs approved for other indications that are being used in a manner considered standard of care for this transplant procedure are allowed~* The patient (and/or their parent/legal guardian), in the opinion of the Investigator, is unable to adhere to the requirements of the study

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Plerixafor 160 μg/kg (Type: EXPERIMENTAL): Patients will receive subcutaneous (SC) injection of 160 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).
- Plerixafor 240 μg/kg (Type: EXPERIMENTAL): Patients will receive subcutaneous (SC) injection of 240 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).
- Plerixafor 320 μg/kg (Type: EXPERIMENTAL): Patients will receive subcutaneous (SC) injection of 320 μg/kg plerixafor in addition to their standard mobilization regimen. Each dose of plerixafor will be administered in the evening 9 to 11 hours prior to apheresis (up to a maximum of 5 apheresis sessions).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete